Array BioPharma Announces Strategic Collaboration With Pfizer
News
Related Biotechnology, Pharmaceutical and Healthcare News
The companies will investigate the safety and efficacy of several novel anti-
cancer combinations, including
Array's
MEK inhibitor, binimetinib, with Pfizer's investigational PARP inhibitor talazoparib, and avelumab, a human monoclonal antibody.
Original Article: Array BioPharma Announces Strategic Collaboration With Pfizer
NEXT ARTICLE
More From BioPortfolio on "Array BioPharma Announces Strategic Collaboration With Pfizer"